SanBio Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

SanBioDer Gewinn des Unternehmens wird voraussichtlich um 4.1% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 53.1% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich sinken um 3.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -443.7% betragen.

Wichtige Informationen

-2.2%

Wachstumsrate der Gewinne

-1.7%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	21.0%
Wachstumsrate der Einnahmen	55.1%
Zukünftige Eigenkapitalrendite	-126.3%
Analystenabdeckung	Low
Zuletzt aktualisiert	02 Jul 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

TSE:4592 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (JPY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
1/31/2027	2,859	-2,133	-2,611	N/A	5
1/31/2026	1,116	-3,174	-3,521	N/A	5
1/31/2025	200	-2,835	1,456	N/A	4
4/30/2024	N/A	-2,162	N/A	N/A	N/A
1/31/2024	N/A	-2,644	-4,819	-4,765	N/A
10/31/2023	N/A	-5,684	N/A	N/A	N/A
7/31/2023	N/A	-5,192	-6,106	-6,094	N/A
4/30/2023	N/A	-5,870	N/A	N/A	N/A
1/31/2023	N/A	-5,559	-7,441	-7,434	N/A
10/31/2022	N/A	-3,320	N/A	N/A	N/A
7/31/2022	N/A	-4,697	-7,080	-7,048	N/A
4/30/2022	N/A	-4,132	N/A	N/A	N/A
1/31/2022	N/A	-4,677	-6,602	-6,546	N/A
10/31/2021	N/A	-1,659	N/A	N/A	N/A
7/31/2021	N/A	-2,312	-6,267	-6,189	N/A
4/30/2021	N/A	-2,738	N/A	N/A	N/A
1/31/2021	N/A	-3,385	-5,353	-5,215	N/A
10/31/2020	23	-6,718	N/A	N/A	N/A
7/31/2020	20	-6,316	-5,619	-5,430	N/A
4/30/2020	258	-5,928	N/A	N/A	N/A
1/31/2020	447	-5,157	-5,823	-5,717	N/A
10/31/2019	597	-4,651	N/A	N/A	N/A
7/31/2019	753	-3,927	-4,626	-4,619	N/A
4/30/2019	772	-2,819	N/A	N/A	N/A
1/31/2019	741	-2,920	-3,974	-3,968	N/A
10/31/2018	687	-2,331	N/A	N/A	N/A
7/31/2018	656	-2,705	-2,111	-2,107	N/A
4/30/2018	525	-3,680	N/A	N/A	N/A
1/31/2018	490	-3,940	N/A	-1,906	N/A
10/31/2017	562	-3,302	N/A	N/A	N/A
7/31/2017	514	-2,966	N/A	-3,099	N/A
4/30/2017	447	-2,655	N/A	N/A	N/A
1/31/2017	949	-1,835	N/A	-1,796	N/A
10/31/2016	833	-2,209	N/A	N/A	N/A
7/31/2016	1,447	-1,693	N/A	-1,290	N/A
4/30/2016	1,515	-1,156	N/A	N/A	N/A
1/31/2016	1,174	-988	N/A	-1,362	N/A
10/31/2015	1,208	-647	N/A	N/A	N/A
1/31/2015	3,229	1,736	N/A	-218	N/A
1/31/2014	204	-589	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 4592 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: 4592 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: 4592 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: 4592Die Einnahmen des Unternehmens (53.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt JP (4.1% pro Jahr).

Hohe Wachstumseinnahmen: 4592Die Einnahmen des Unternehmens (53.1% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 4592 wird voraussichtlich in 3 Jahren unrentabel sein.

SanBio Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 20% to JP¥960

Price target increased by 23% to JP¥983

Price target decreased by 30% to JP¥1,214

Price target increased by 18% to JP¥2,100

Forecast to breakeven in 2027

Consensus revenue estimates fall by 15%

Recent updates

Price target increased by 20% to JP¥960

Price target increased by 23% to JP¥983

New major risk - Revenue and earnings growth

SanBio Company Limited Announces Update on Status of Manufacturing and Marketing Approval for Sb623 Chronic Traumatic Brain Injury Program in Japan

SanBio Company Limited to Report Q1, 2025 Results on Jun 13, 2024

New major risk - Revenue and earnings growth

Price target decreased by 30% to JP¥1,214

SanBio Company Limited, Annual General Meeting, Apr 24, 2024

SanBio Company Limited, Annual General Meeting, Apr 24, 2024

Price target increased by 18% to JP¥2,100

Forecast to breakeven in 2027

SanBio Company Limited to Report Fiscal Year 2024 Results on Mar 18, 2024

Sanbio Co., Ltd. Provides Update on Status of Manufacturing and Marketing Approval for Sb623 Chronic Traumatic Brain Injury Program in Japan

New major risk - Financial position

SanBio Company Limited Provides Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan

SanBio Company Limited to Report Q3, 2024 Results on Dec 14, 2023

SanBio Company Limited to Report Q2, 2024 Results on Sep 15, 2023

Consensus revenue estimates fall by 15%

SanBio Co., Ltd. Updates on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury Program in Japan

Price target increased by 13% to JP¥2,290

No longer forecast to breakeven

SanBio Company Limited to Report Q1, 2024 Results on Jun 14, 2023

Price target increased by 12% to JP¥2,465

No longer forecast to breakeven

Price target increased by 12% to JP¥2,465

SanBio Company Limited to Report Fiscal Year 2023 Results on Mar 16, 2023

Forecast to breakeven in 2026

SanBio Co., Ltd. Announces Board Changes

SanBio Company Limited Provides Earnings Guidance for the Fiscal Year Ending January 31, 2023

Less than half of directors are independent

SanBio Company Limited to Report Q3, 2023 Results on Dec 15, 2022

Sanbio Company Limited Provides Earnings Guidance for the Fiscal Year Ending January 31, 2023

Price target decreased to JP¥2,233

SanBio Company Announces Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan

Keizo Nakada to Join Sanbio as Corporate Officer and Head of Production

Price target decreased to JP¥2,200

SanBio Company Limited Provides Consolidated Earnings Guidance for the First Half and Full Year Ending January 31, 2023

SanBio Company Limited Appoints Andrew Liu as Chief Strategy Officer

Less than half of directors are independent

Sanbio Group Provides an Update on One-Year Analysis of the Phase 2 STEMTRA Trial

Sanbio Company Limited Announces Filing with Japan’S Ministry of Health, Labour, and Welfare for Manufacture and Marketing Approval as A Regenerative Medicine Product for the Investigational Product Sb623

Price target increased to JP¥2,900

SanBio Company Limited announced that it expects to receive ¥33.75 million in funding from Nomura Securities Co., Ltd.

SanBio Company Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending January 31, 2022

SanBio Company Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending January 31, 2022

Corporate Officer & Business Head of Japan/Asia Hiroshi Yamamoto has left the company

Price target increased to JP¥2,660

SanBio Company Limited Provides Consolidated Earnings Guidance for the First Half and Full Year of the Fiscal Year Ending January 31, 2022

SanBio Company Limited Provides Earnings Guidance for the First Half and Full Year of the Fiscal Year Ending January 31, 2022

Sanbio Company Limited Presents STEMTRA Phase 2 Trial Results At the 44Th Annual Meeting of the Japan Society of Neurotraumatology

SanBio Company Limited to Report Fiscal Year 2021 Results on Mar 17, 2021

SanBio Company Limited Announces Publication of STEMTRA Phase 2 Interim Analysis for SB623 in Neurology

Price target lowered to JP¥2,683

New 90-day low: JP¥1,388

Price target lowered to JP¥2,683

SanBio Company Limited to Report Q3, 2021 Results on Dec 15, 2020

Tokio Marine & Nichido Fire Insurance Co., Ltd. agreed to acquire 9.74% stake in CareNet, Inc. (TSE:2150) from SanBio Company Limited (TSE:4592).

SanBio Company Limited Appoints Hiroyasu Narita as Head of Clinical Development, Effective from October 1, 2020

SanBio Company Limited to Report Q2, 2021 Results on Sep 14, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken